0
     

Report Added
Report already added
Human Granulocyte Colony-stimulating Factor Market - Global Outlook and Forecast 2022-2028

Human Granulocyte Colony-stimulating Factor Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Human Granulocyte Colony-stimulating Factor in global, including the following market information:

Global Human Granulocyte Colony-stimulating Factor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Granulocyte Colony-stimulating Factor Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Granulocyte Colony-stimulating Factor companies in 2021 (%)
The global Human Granulocyte Colony-stimulating Factor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
300μg/Dose Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Granulocyte Colony-stimulating Factor include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC and Wuzhong Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Granulocyte Colony-stimulating Factor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Human Granulocyte Colony-stimulating Factor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Type, 2021 (%)
300μg/Dose
150μg/Dose
75μg/Dose
Others
Global Human Granulocyte Colony-stimulating Factor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Human Granulocyte Colony-stimulating Factor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Granulocyte Colony-stimulating Factor revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Granulocyte Colony-stimulating Factor revenues share in global market, 2021 (%)
Key companies Human Granulocyte Colony-stimulating Factor sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Granulocyte Colony-stimulating Factor sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Human Granulocyte Colony-stimulating Factor Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Granulocyte Colony-stimulating Factor Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Human Granulocyte Colony-stimulating Factor Overall Market Size
2.1 Global Human Granulocyte Colony-stimulating Factor Market Size: 2021 VS 2028
2.2 Global Human Granulocyte Colony-stimulating Factor Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Human Granulocyte Colony-stimulating Factor Sales: 2017-2028
3 Company Landscape
3.1 Top Human Granulocyte Colony-stimulating Factor Players in Global Market
3.2 Top Global Human Granulocyte Colony-stimulating Factor Companies Ranked by Revenue
3.3 Global Human Granulocyte Colony-stimulating Factor Revenue by Companies
3.4 Global Human Granulocyte Colony-stimulating Factor Sales by Companies
3.5 Global Human Granulocyte Colony-stimulating Factor Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Human Granulocyte Colony-stimulating Factor Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Human Granulocyte Colony-stimulating Factor Product Type
3.8 Tier 1, Tier 2 and Tier 3 Human Granulocyte Colony-stimulating Factor Players in Global Market
3.8.1 List of Global Tier 1 Human Granulocyte Colony-stimulating Factor Companies
3.8.2 List of Global Tier 2 and Tier 3 Human Granulocyte Colony-stimulating Factor Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Human Granulocyte Colony-stimulating Factor Market Size Markets, 2021 & 2028
4.1.2 300μg/Dose
4.1.3 150μg/Dose
4.1.4 75μg/Dose
4.1.5 Others
4.2 By Type - Global Human Granulocyte Colony-stimulating Factor Revenue & Forecasts
4.2.1 By Type - Global Human Granulocyte Colony-stimulating Factor Revenue, 2017-2022
4.2.2 By Type - Global Human Granulocyte Colony-stimulating Factor Revenue, 2023-2028
4.2.3 By Type - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
4.3 By Type - Global Human Granulocyte Colony-stimulating Factor Sales & Forecasts
4.3.1 By Type - Global Human Granulocyte Colony-stimulating Factor Sales, 2017-2022
4.3.2 By Type - Global Human Granulocyte Colony-stimulating Factor Sales, 2023-2028
4.3.3 By Type - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
4.4 By Type - Global Human Granulocyte Colony-stimulating Factor Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Human Granulocyte Colony-stimulating Factor Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Human Granulocyte Colony-stimulating Factor Revenue & Forecasts
5.2.1 By Application - Global Human Granulocyte Colony-stimulating Factor Revenue, 2017-2022
5.2.2 By Application - Global Human Granulocyte Colony-stimulating Factor Revenue, 2023-2028
5.2.3 By Application - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
5.3 By Application - Global Human Granulocyte Colony-stimulating Factor Sales & Forecasts
5.3.1 By Application - Global Human Granulocyte Colony-stimulating Factor Sales, 2017-2022
5.3.2 By Application - Global Human Granulocyte Colony-stimulating Factor Sales, 2023-2028
5.3.3 By Application - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
5.4 By Application - Global Human Granulocyte Colony-stimulating Factor Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Human Granulocyte Colony-stimulating Factor Market Size, 2021 & 2028
6.2 By Region - Global Human Granulocyte Colony-stimulating Factor Revenue & Forecasts
6.2.1 By Region - Global Human Granulocyte Colony-stimulating Factor Revenue, 2017-2022
6.2.2 By Region - Global Human Granulocyte Colony-stimulating Factor Revenue, 2023-2028
6.2.3 By Region - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
6.3 By Region - Global Human Granulocyte Colony-stimulating Factor Sales & Forecasts
6.3.1 By Region - Global Human Granulocyte Colony-stimulating Factor Sales, 2017-2022
6.3.2 By Region - Global Human Granulocyte Colony-stimulating Factor Sales, 2023-2028
6.3.3 By Region - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028
6.4.2 By Country - North America Human Granulocyte Colony-stimulating Factor Sales, 2017-2028
6.4.3 US Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.4.4 Canada Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.4.5 Mexico Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028
6.5.2 By Country - Europe Human Granulocyte Colony-stimulating Factor Sales, 2017-2028
6.5.3 Germany Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.4 France Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.5 U.K. Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.6 Italy Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.7 Russia Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.8 Nordic Countries Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.5.9 Benelux Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028
6.6.2 By Region - Asia Human Granulocyte Colony-stimulating Factor Sales, 2017-2028
6.6.3 China Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.6.4 Japan Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.6.5 South Korea Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.6.6 Southeast Asia Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.6.7 India Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028
6.7.2 By Country - South America Human Granulocyte Colony-stimulating Factor Sales, 2017-2028
6.7.3 Brazil Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.7.4 Argentina Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales, 2017-2028
6.8.3 Turkey Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.8.4 Israel Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.8.5 Saudi Arabia Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
6.8.6 UAE Human Granulocyte Colony-stimulating Factor Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Chugai Pharmaceutical
7.1.1 Chugai Pharmaceutical Corporate Summary
7.1.2 Chugai Pharmaceutical Business Overview
7.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.1.5 Chugai Pharmaceutical Key News
7.2 Kyowa Hakko Kirin
7.2.1 Kyowa Hakko Kirin Corporate Summary
7.2.2 Kyowa Hakko Kirin Business Overview
7.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.2.5 Kyowa Hakko Kirin Key News
7.3 Sanway
7.3.1 Sanway Corporate Summary
7.3.2 Sanway Business Overview
7.3.3 Sanway Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.3.4 Sanway Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.3.5 Sanway Key News
7.4 GenSci
7.4.1 GenSci Corporate Summary
7.4.2 GenSci Business Overview
7.4.3 GenSci Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.4.4 GenSci Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.4.5 GenSci Key News
7.5 SL PHARM
7.5.1 SL PHARM Corporate Summary
7.5.2 SL PHARM Business Overview
7.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.5.5 SL PHARM Key News
7.6 Kexing Bioproducts
7.6.1 Kexing Bioproducts Corporate Summary
7.6.2 Kexing Bioproducts Business Overview
7.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.6.5 Kexing Bioproducts Key News
7.7 Qilu Pharmaceutical
7.7.1 Qilu Pharmaceutical Corporate Summary
7.7.2 Qilu Pharmaceutical Business Overview
7.7.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.7.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.7.5 Qilu Pharmaceutical Key News
7.8 CSPC
7.8.1 CSPC Corporate Summary
7.8.2 CSPC Business Overview
7.8.3 CSPC Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.8.4 CSPC Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.8.5 CSPC Key News
7.9 Wuzhong Pharmaceutical
7.9.1 Wuzhong Pharmaceutical Corporate Summary
7.9.2 Wuzhong Pharmaceutical Business Overview
7.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.9.5 Wuzhong Pharmaceutical Key News
7.10 Quangang Pharmaceutical
7.10.1 Quangang Pharmaceutical Corporate Summary
7.10.2 Quangang Pharmaceutical Business Overview
7.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.10.5 Quangang Pharmaceutical Key News
7.11 Huabei Pharmaceutical
7.11.1 Huabei Pharmaceutical Corporate Summary
7.11.2 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Business Overview
7.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.11.5 Huabei Pharmaceutical Key News
7.12 Harbin Pharmaceutical
7.12.1 Harbin Pharmaceutical Corporate Summary
7.12.2 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Business Overview
7.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.12.5 Harbin Pharmaceutical Key News
7.13 Amoytop Biotech
7.13.1 Amoytop Biotech Corporate Summary
7.13.2 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Business Overview
7.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.13.5 Amoytop Biotech Key News
7.14 Jiuyuan Gene Engineering
7.14.1 Jiuyuan Gene Engineering Corporate Summary
7.14.2 Jiuyuan Gene Engineering Business Overview
7.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.14.5 Jiuyuan Gene Engineering Key News
7.15 Four Rings Biopharmaceutical
7.15.1 Four Rings Biopharmaceutical Corporate Summary
7.15.2 Four Rings Biopharmaceutical Business Overview
7.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Major Product Offerings
7.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales and Revenue in Global (2017-2022)
7.15.5 Four Rings Biopharmaceutical Key News
8 Global Human Granulocyte Colony-stimulating Factor Production Capacity, Analysis
8.1 Global Human Granulocyte Colony-stimulating Factor Production Capacity, 2017-2028
8.2 Human Granulocyte Colony-stimulating Factor Production Capacity of Key Manufacturers in Global Market
8.3 Global Human Granulocyte Colony-stimulating Factor Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Human Granulocyte Colony-stimulating Factor Supply Chain Analysis
10.1 Human Granulocyte Colony-stimulating Factor Industry Value Chain
10.2 Human Granulocyte Colony-stimulating Factor Upstream Market
10.3 Human Granulocyte Colony-stimulating Factor Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Human Granulocyte Colony-stimulating Factor Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Human Granulocyte Colony-stimulating Factor in Global Market
Table 2. Top Human Granulocyte Colony-stimulating Factor Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Human Granulocyte Colony-stimulating Factor Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Companies, 2017-2022
Table 5. Global Human Granulocyte Colony-stimulating Factor Sales by Companies, (K Units), 2017-2022
Table 6. Global Human Granulocyte Colony-stimulating Factor Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Human Granulocyte Colony-stimulating Factor Price (2017-2022) & (US$/Unit)
Table 8. Global Manufacturers Human Granulocyte Colony-stimulating Factor Product Type
Table 9. List of Global Tier 1 Human Granulocyte Colony-stimulating Factor Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Human Granulocyte Colony-stimulating Factor Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2017-2022
Table 15. By Type - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2023-2028
Table 16. By Application – Global Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2017-2022
Table 20. By Application - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2023-2028
Table 21. By Region – Global Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Human Granulocyte Colony-stimulating Factor Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2017-2022
Table 25. By Region - Global Human Granulocyte Colony-stimulating Factor Sales (K Units), 2023-2028
Table 26. By Country - North America Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2017-2022
Table 29. By Country - North America Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2023-2028
Table 30. By Country - Europe Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2017-2022
Table 33. By Country - Europe Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2023-2028
Table 34. By Region - Asia Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2017-2022
Table 37. By Region - Asia Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2023-2028
Table 38. By Country - South America Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2017-2022
Table 41. By Country - South America Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales, (K Units), 2023-2028
Table 46. Chugai Pharmaceutical Corporate Summary
Table 47. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 48. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 49. Kyowa Hakko Kirin Corporate Summary
Table 50. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product Offerings
Table 51. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 52. Sanway Corporate Summary
Table 53. Sanway Human Granulocyte Colony-stimulating Factor Product Offerings
Table 54. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 55. GenSci Corporate Summary
Table 56. GenSci Human Granulocyte Colony-stimulating Factor Product Offerings
Table 57. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 58. SL PHARM Corporate Summary
Table 59. SL PHARM Human Granulocyte Colony-stimulating Factor Product Offerings
Table 60. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 61. Kexing Bioproducts Corporate Summary
Table 62. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product Offerings
Table 63. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 64. Qilu Pharmaceutical Corporate Summary
Table 65. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 66. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 67. CSPC Corporate Summary
Table 68. CSPC Human Granulocyte Colony-stimulating Factor Product Offerings
Table 69. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 70. Wuzhong Pharmaceutical Corporate Summary
Table 71. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 72. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 73. Quangang Pharmaceutical Corporate Summary
Table 74. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 75. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 76. Huabei Pharmaceutical Corporate Summary
Table 77. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 78. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 79. Harbin Pharmaceutical Corporate Summary
Table 80. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 81. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 82. Amoytop Biotech Corporate Summary
Table 83. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product Offerings
Table 84. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 85. Jiuyuan Gene Engineering Corporate Summary
Table 86. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product Offerings
Table 87. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 88. Four Rings Biopharmaceutical Corporate Summary
Table 89. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product Offerings
Table 90. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 91. Human Granulocyte Colony-stimulating Factor Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 92. Global Human Granulocyte Colony-stimulating Factor Capacity Market Share of Key Manufacturers, 2020-2022
Table 93. Global Human Granulocyte Colony-stimulating Factor Production by Region, 2017-2022 (K Units)
Table 94. Global Human Granulocyte Colony-stimulating Factor Production by Region, 2023-2028 (K Units)
Table 95. Human Granulocyte Colony-stimulating Factor Market Opportunities & Trends in Global Market
Table 96. Human Granulocyte Colony-stimulating Factor Market Drivers in Global Market
Table 97. Human Granulocyte Colony-stimulating Factor Market Restraints in Global Market
Table 98. Human Granulocyte Colony-stimulating Factor Raw Materials
Table 99. Human Granulocyte Colony-stimulating Factor Raw Materials Suppliers in Global Market
Table 100. Typical Human Granulocyte Colony-stimulating Factor Downstream
Table 101. Human Granulocyte Colony-stimulating Factor Downstream Clients in Global Market
Table 102. Human Granulocyte Colony-stimulating Factor Distributors and Sales Agents in Global Market

List of Figures
Figure 1. Human Granulocyte Colony-stimulating Factor Segment by Type
Figure 2. Human Granulocyte Colony-stimulating Factor Segment by Application
Figure 3. Global Human Granulocyte Colony-stimulating Factor Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Human Granulocyte Colony-stimulating Factor Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Human Granulocyte Colony-stimulating Factor Revenue, 2017-2028 (US$, Mn)
Figure 7. Human Granulocyte Colony-stimulating Factor Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Human Granulocyte Colony-stimulating Factor Revenue in 2021
Figure 9. By Type - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 10. By Type - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 11. By Type - Global Human Granulocyte Colony-stimulating Factor Price (US$/Unit), 2017-2028
Figure 12. By Application - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 13. By Application - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 14. By Application - Global Human Granulocyte Colony-stimulating Factor Price (US$/Unit), 2017-2028
Figure 15. By Region - Global Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 16. By Region - Global Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 17. By Country - North America Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 18. By Country - North America Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 19. US Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 24. Germany Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 25. France Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 33. China Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 37. India Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 39. By Country - South America Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 40. Brazil Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales Market Share, 2017-2028
Figure 44. Turkey Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Human Granulocyte Colony-stimulating Factor Revenue, (US$, Mn), 2017-2028
Figure 48. Global Human Granulocyte Colony-stimulating Factor Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Human Granulocyte Colony-stimulating Factor by Region, 2021 VS 2028
Figure 50. Human Granulocyte Colony-stimulating Factor Industry Value Chain
Figure 51. Marketing Channels

Report Title: Human Granulocyte Colony-stimulating Factor Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update